Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Kathrine, Grell"'
Autor:
Rikke Hebo Larsen, Cecilie Utke Rank, Kathrine Grell, Lisbeth Nørgaard Møller, Ulrik Malthe Overgaard, Peter Kampmann, Jacob Nersting, Matilda Degn, Stine Nygaard Nielsen, Helle Holst, Birgitte Klug Albertsen, Peder Skov Wehner, Michael Thude Callesen, Jukka Kanerva, Thomas Leth Frandsen, Bodil Als-Nielsen, Lisa Lyngsie Hjalgrim, Kjeld Schmiegelow
Publikováno v:
Haematologica, Vol 106, Iss 11 (2021)
Maintenance therapy containing methotrexate and 6-mercapto - purine is essential to cure acute lymphoblastic leukemia (ALL). Cytotoxicity is elicited by incorporation of thioguanine nucleotides into DNA (DNA-TG), and higher leukocyte DNA-TG is associ
Externí odkaz:
https://doaj.org/article/824bdbd3c5524dbba9ba9095b3184cb4
Autor:
Kjeld Schmiegelow, Trine-Lise Lambine, Liv Andrés-Jensen, Mette Tiedemann Skipper, Kristian Mielke Christensen, Pia Hedegaard Johnsen, Katrine Aagaard Myhr, Martin Kaj Fridh, Kathrine Grell, A. M. L. Pedersen, Sune Leisgaard Mørck Rubak, Martin Ballegaard, Arne Hørlyck, Rikke Beck Jensen, Kim Gjerum Nielsen, Ruta Tuckuviene, Peder Skov Wehner, Birgitte Klug Albertsen, Thomas Leth Frandsen
Publikováno v:
BMJ Open, Vol 11, Iss 2 (2021)
Introduction More than 90% of patients diagnosed with childhood acute lymphoblastic leukaemia (ALL) today will survive. However, half of the survivors are expected to experience therapy-related chronic or late occurring adverse effects, reducing qual
Externí odkaz:
https://doaj.org/article/24b4ea6d4fa847c2a2ca828386aa999b
Autor:
Pernille Rudebeck Mogensen, Kathrine Grell, Kjeld Schmiegelow, Ulrik Malthe Overgaard, Benjamin Ole Wolthers, Signe Sloth Mogensen, Allan Vaag, Thomas Leth Frandsen
Publikováno v:
PLoS ONE, Vol 15, Iss 4, p e0231209 (2020)
As survival of acute lymphoblastic leukemia (ALL) exceeds 90%, limiting therapy-related toxicity has become a key challenge. Cardio-metabolic dysfunction is a challenge during and after childhood ALL therapy. In a single center study, we measured tri
Externí odkaz:
https://doaj.org/article/65910bc64cd8432e8a934fed23bc9f52
Autor:
Signe Sloth Mogensen, Kjeld Schmiegelow, Kathrine Grell, Birgitte Klug Albertsen, Peder Skov Wehner, Peter Kampmann, Thomas Leth Frandsen
Publikováno v:
Haematologica, Vol 102, Iss 5 (2017)
Externí odkaz:
https://doaj.org/article/13b3901b3b31444790f959657f6fa6b5
Autor:
Sofie Gottschalk Højfeldt, Kathrine Grell, Lone Hvitfeldt, Peder Skov Wehner, Jesper Bjerre, Birgitte Klug Albertsen
Publikováno v:
Højfeldt, S G, Grell, K, Hvitfeldt, L, Wehner, P S, Bjerre, J & Albertsen, B K 2023, ' Correlation between asparaginase enzyme activity levels and coagulation parameters during childhood acute lymphoblastic leukemia treatment ', Pediatric Blood & Cancer, vol. 70, no. 2, e30085 . https://doi.org/10.1002/pbc.30085
Højfeldt, S G, Grell, K, Hvitfeldt, L, Wehner, P S, Bjerre, J & Albertsen, B K 2022, ' Correlation between asparaginase enzyme activity levels and coagulation parameters during childhood acute lymphoblastic leukemia treatment ', Pediatric Blood and Cancer . https://doi.org/10.1002/pbc.30085
Højfeldt, S G, Grell, K, Hvitfeldt, L, Wehner, P S, Bjerre, J & Albertsen, B K 2022, ' Correlation between asparaginase enzyme activity levels and coagulation parameters during childhood acute lymphoblastic leukemia treatment ', Pediatric Blood and Cancer . https://doi.org/10.1002/pbc.30085
Thromboembolism is a serious toxicity in the treatment of acute lymphoblastic leukemia (ALL), but little is known about the correlation between asparaginase enzyme activity (ASA) levels and coagulation parameters. We included 65 non-high risk ALL pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cee9aca82e042582069c03130d195397
https://pubmed.ncbi.nlm.nih.gov/36377699
https://pubmed.ncbi.nlm.nih.gov/36377699
Autor:
Kathrine Grell, Lisa Lyngsie Hjalgrim, Anja Möricke, Jacob Nersting, Jaitri Joshi, Bruce Bostrom, Petter Quist-Paulsen, Kim Dalhoff, Bendik Lund, Kristi Lepik, Anthony V. Moorman, Goda Vaitkevičienė, Kjeld Schmiegelow, Daniel Murdy, Jukka Kanerva, Olafur G. Jonsson, Linea Natalie Toksvang, Bodil Als-Nielsen, Martin Zimmermann, Stine Nygaard Nielsen, Ajay Vora, Matilda Degn, Laimonas Griskevicius, Jonas Abrahamsson
Publikováno v:
Leukemia. 36:33-41
Methotrexate/6-mercaptopurine maintenance therapy improves acute lymphoblastic leukemia (ALL) outcome. Cytotoxicity is mediated by DNA incorporation of thioguanine nucleotides (DNA-TG). We investigated the association of DNA-TG to relapse risk in 1 9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e569cafaa116267961cde2bf2ff0793f
https://doi.org/10.1038/s41375-021-01182-9
https://doi.org/10.1038/s41375-021-01182-9
Autor:
Jacob Nersting, Nina Toft, Linea Natalie Toksvang, Thomas Frandsen, Stine Nygaard Nielsen, Laimonas Griskevicius, Signe Sloth Mogensen, Riitta Niinimäki, Joel Joelsson, Ulrik Malthe Overgaard, Olafur G. Jonsson, Kjeld Schmiegelow, Jonas Abrahamsson, Cecilie Utke Rank, Kathrine Grell, Arja Harila-Saari, Petter Quist-Paulsen, Goda Vaitkevičienė, Liv Andrés-Jensen
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:911-917
Osteonecrosis is a burdensome treatment-related toxicity that is mostly diagnosed during or soon after 6-mercaptopurine (6MP)/methotrexate (MTX) maintenance therapy for acute lymphoblastic leukemia (ALL), possibly indicating a pathogenic role of thes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8054a20906d26aad2e3db53924c15560
https://doi.org/10.1007/s00280-021-04316-z
https://doi.org/10.1007/s00280-021-04316-z
Autor:
Kjeld Schmiegelow, Bendik Lund, Kathrine Grell, Stine Nygaard Nielsen, Goda Vaitkeviciene, Jukka Kanerva, Malin Lindqvist Appell, Lisa Lyngsie Hjalgrim, Jacob Nersting, Linea Natalie Toksvang, Jonas Abrahamsson, Kaie Pruunsild, Olafur G. Jonsson
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:271-279
6-mercaptopurine(6MP)/methotrexate maintenance therapy is essential to reduce relapse of childhood acute lymphoblastic leukemia (ALL). Common germline variants in TPMT cause low activity of thiopurine methyltransferase (TPMT) and higher 6MP metabolit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f99ade3e3597a1b0fa951db9d7eb314
https://doi.org/10.1007/s00280-021-04281-7
https://doi.org/10.1007/s00280-021-04281-7
Autor:
Lisa Lyngsie Hjalgrim, Jacob Nersting, Kathrine Grell, Bodil Als-Nielsen, Kjeld Schmiegelow, Matilda Degn, Rikke Hebo Larsen
Publikováno v:
Cancer Chemotherapy and Pharmacology. 88:53-60
Methotrexate (MTX)/6-Mercaptopurine (6MP)-based maintenance therapy is crucial to cure childhood acute lymphoblastic leukemia (ALL). Cytotoxicity is mediated by incorporation of thioguanine nucleotides (TGN) into DNA (DNA-TG) with higher levels in le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac2397a92eb22e1183339445d03c577a
https://doi.org/10.1007/s00280-020-04219-5
https://doi.org/10.1007/s00280-020-04219-5
Autor:
Stine Nygaard Nielsen, Jacob Nersting, Anthony V. Moorman, Ajay Vora, Linea Natalie Toksvang, Daniel Murdy, Kathrine Grell, Kjeld Schmiegelow
Publikováno v:
Leukemia. 36:555-557
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f257a460a9380a37edf21875521f68f
https://doi.org/10.1038/s41375-021-01420-0
https://doi.org/10.1038/s41375-021-01420-0